“…The authors claimed that each of the above three systems had been experimentally validated, and all were consistent with their polymorph selection design principle. However, because of the uncontrollability of the nucleation process, the existence of back-mixing in the MSMPR crystallizer and the nonideal 43 cyclosporin, 23,42 isothiocyanate, 44,45 prexasertib monolactate monohydrate, 46 L-alanine, 21 aliskiren hemifumarate, 47 carbamazepine, 48 D-/L-threonine, 49 albuterol, 50 azithromycin, 50 melitracen hydrochloride 51,52 continuous plug flow crystallizer benzoic acid, 26,53 acetaminophen, 54 triacylglycerol, 55−58 griseofulvin, 59 brivaracetam, 60,61 ketoconazole, 62 paracetamol, 63 acetylsalicylic acid, 64 flufenamic acid 62 continuous oscillatory baffled crystallizer L-glutamic acid, 28 biuret, 65 paracetamol, 66 melamine, 67 butyl paraben, 68 urea, 65 adipic acid, 69 α-lactose monohydrate, 70 salicylic acid, 71 aspirin 72 continuous segmented flow crystallizer L-asparagine monohydrate, 32,73,74 60 conducted a series of studies on brivaracetam in continuous-flow tubular crystallization, applying two crystallization strategies. With the cooling crystallization strategy, the extreme cooling condition of 20 °C/s was implemented, and high supersaturation was generated to obtain the desired crystal form.…”